glp-1 drugs and crohn's disease Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, therapeutic potential ADJUNCTIVE GLP-1 RECEPTOR AGONISTS IN
Description
The introduction of GLP-1s for weight loss has been a dysfunctional mess, thanks to pharmaceutical companies, insurance plans, pharmacy chains, and the federal government.
95% CI 0.750.98, p=0.03), Dulaglutide (RR 0.82, 95% CI 0.700.96, p=0.02), Albiglutide (RR 0.93,95% CI 0.791.10, p=0.40), Exenatide (RR 0.93, 95% CI 0.741.18, p=0.55), Lixisenatide (RR 0.83, 95% CI 0.621.12, p=0.22), and Efpeglenatide (RR 0.76, 95% CI 0.461.24, p=0.27)
with a GLP-1
Discover how to access GLP-1 drugs like Wegovy & Ozempic without breaking the bank
GLP-1 drugs are widely used for diabetes and weight loss, but their potential to transform healthcare is growing
